A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma

REFERENCES

• Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Act. Neuropathol (Berl) 2007; 114(2)97–109
   PubMed Web of Science ®Google Scholar
• Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. 2001; 19(2)509–518
   PubMed Web of Science ®Google Scholar
• Levin V. A., Silver P., Hannigan J., Wara W. M., Gutin P. H., Davis R. L., Wilson C. B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18(2)321–324
   PubMed Web of Science ®Google Scholar
• Yung W. K., Prados M. D., Yaya-Tur R., Rosenfeld S. S., Brada M., Friedman H. S., Albright R., Olson J., Chang S. M., O'Neill A. M., Friedman A. H., Bruner J., Yue N., Dugan M., Zaknoen S., Levin V. A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 1999; 17(9)2762–2771
   PubMed Web of Science ®Google Scholar
• Brada M., Hoang-Xuan K., Rampling R., Dietrich P. Y., Dirix L. Y., Macdonald D., Heimans J. J., Zonnenberg B. A., Bravo-Marques J. M., Henriksson R., Stupp R., Yue N., Bruner J., Dugan M., Rao S., Zaknoen S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 2001; 12(2)259–266
   PubMed Web of Science ®Google Scholar
• Chang S. M., Theodosopoulos P., Lamborn K., Malec M., Rabbitt J., Page M., Prados M. D. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004; 100(3)605–611
   PubMed Web of Science ®Google Scholar
• Everaert E., Neyns B., Joosens E., Strauven T., Branle F., Menten J. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J. Neurooncol. 2004; 70(1)37–48
   PubMed Web of Science ®Google Scholar
• Yung W. K., Albright R. E., Olson J., Fredericks R., Fink K., Prados M. D., Brada M., Spence A., Hohl R. J., Shapiro W., Glantz M., Greenberg H., Selker R. G., Vick N. A., Rampling R., Friedman H., Phillips P., Bruner J., Yue N., Osoba D., Zaknoen S., Levin V. A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer. 2000; 83(5)588–593
   Google Scholar
• Tolcher A. W., Gerson S. L., Denis L., Geyer C., Hammond L. A., Patnaik A., Goetz A. D., Schwartz G., Edwards T., Reyderman L., Statkevich P., Cutler D. L., Rowinsky E. K. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer. 2003; 88(7)1004–1011
   PubMed Web of Science ®Google Scholar
• Michotte A., Neyns B., Chaskis C., Sadones J., In't Veld P. Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta. Neurol. Belg. 2004; 104(4)148–153
   PubMed Web of Science ®Google Scholar
• Macdonald D. R., Cascino T. L., Schold S. C., Cairncross J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 1990; 8(7)1277–1280
   PubMed Web of Science ®Google Scholar
• Esteller M., Garcia-Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B., Herman J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000; 343(19)1350–1354
   PubMed Web of Science ®Google Scholar
• Hegi M. E., Diserens A. C., Gorlia T., Hamou M. F., de Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005; 352(10)997–1003
   PubMed Web of Science ®Google Scholar
• Paz M. F., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., Garcia-Lopez J. L., Piquer J., Safont M. J., Balana C., Sanchez-Cespedes M., Garcia-Villanueva M., Arribas L., Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004; 10(15)4933–4938
   PubMed Web of Science ®Google Scholar
• Tosoni A., Cavallo G., Ermani M., Scopece L., Franceschi E., Ghimenton C., Gardiman M., Pasetto L., Blatt V., Brandes A. A. Is protracted low-dose temozolomide feasible in glioma patients?. Neurology 2006; 66(3)427–429
   PubMed Web of Science ®Google Scholar
• Brandes A. A., Tosoni A., Cavallo G., Bertorelle R., Gioia V., Franceschi E., Biscuola M., Blatt V., Crino L., Ermani M. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br. J. Cancer. 2006; 95(9)1155–1160
   PubMed Web of Science ®Google Scholar
• Wick A., Felsberg J., Steinbach J. P., Herrlinger U., Platten M., Blaschke B., Meyermann R., Reifenberger G., Weller M., Wick W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 2007; 25(22)3357–3361
   PubMed Web of Science ®Google Scholar
• Wick W., Steinbach J. P., Kuker W. M., Dichgans J., Bamberg M., Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004; 62(11)2113–2115
   PubMed Web of Science ®Google Scholar
• Wick W., Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J. Clin. Oncol. 2005; 23(18)4235–4236, author reply 4236
   PubMed Web of Science ®Google Scholar
• Su Y. B., Sohn S., Krown S. E., Livingston P. O., Wolchok J. D., Quinn C., Williams L., Foster T., Sepkowitz K. A., Chapman P. B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 2004; 22(4)610–616
   PubMed Web of Science ®Google Scholar
• Stupp R., Dietrich P.-Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., Meuli R., Janzer R., Pizzolato G., Miralbell R., Porchet F., Regli L., de Tribolet N., Mirimanoff R. O., Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002; 20(5)1375–1382
   PubMed Web of Science ®Google Scholar
• van den Bent M. J., Delattre J., Brandes A. A., Taphoorn M. J., Hoang Xuan K., Bernsen H., Frenay M., Grisold W., Gorlia T., Lacombe D. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma [abstract]. J. Clin. Oncol. 2005; 23: 114s, (suppl). Abstract 1503
   Web of Science ®Google Scholar
• Cairncross G., Seiferheld W., Shaw E., Jenkins R., Scheithauer B., Brachman D., Buckner J., Fink K., Souhami L., Curran W. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02 [abstract]. J. Clin. Oncol. 2004; 23: 107, (suppl)(14s). Abstract 1500
   Google Scholar
• Chahlavi A., Kanner A., Peereboom D., Staugaitis S. M., Elson P., Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J. Neurooncol. 2003; 61(3)267–273
   PubMed Web of Science ®Google Scholar
• Buttolo L. G., Giunta F., Ferrari V. D., Grisanti S., Marini G., Mortini P. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: a 6-year experience [abstract]. J. Clin. Oncol. 2006; 24: 60s, (suppl)(18S). Abstract 1511
   Web of Science ®Google Scholar
• Berrocal A., Pereze-Segura P., Gil M., Balana C., Yaya-Tur R., Rodriguez J., Reynes G., Garcia-Lopez J. L., Gallego O., Group G. C. Phase II study of extended schedule temozolomide in refractory gliomas [abstract]. J. Clin. Oncol. 2006; 24: 62s, (suppl)(18S) Abstract 1516
   Web of Science ®Google Scholar
• Rizek P., Morrison T., Cashman R., Haller T., Perry J. Low-dose temozolomide chemotherapy is active in recurrent malignant glioma, even following progression on conventional 5/28 day treatment: results of a practice audit [abstract]. Can. J. Neurol. Sci. 2004; 31: S9, (suppl 2)(3). Abstract MED-6
   Google Scholar
• US National Institutes of Health. Radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma, Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00304031?order=1. Accessed September 24, 2007
   Google Scholar
• European Organisation for Research and Treatment of Cancer: Brain tumour group: ongoing trials. Available at http://groups.eortc.be/brain/html/trials.html. Accessed September 24, 2007
   Google Scholar